Kornimate/medical-research-clean huggingface dataset:
von willebrand factor and protein c ratio in graft function after liver transplant

Conditions: Liver Transplant; Complications

Summary: in liver cirrhosis (lc),the activity of von willebrand factor (vwf)-cleaving enzyme adamts13 is reduced in lc patients and consequent progression of liver injury. remarkably, it has been reported that a severe vwf/adamts13 imbalance develops during liver transplantation (lt) and persists even after lt. such changes are thought to contribute to postoperative thrombotic complications, which may lead to early adverse events of thrombotic microangiopathy after living-donor lt (ldlt). we investigated whether vwfpcr could predict ead or graft failure following lt and compared it with fviiipcr, procoagulant, such as vwf and fviii and anticoagulant, such as pc.


Eligibility criteria:
inclusion criteria: patients who underwent lt exclusion criteria: deceased-donor liver transplant, and insufficient data, abo-incompatible lt
tissue and clinical characterisation of temporomandibular joint diseases

Conditions: Temporomandibular Joint Disorders; Temporomandibular Arthritis; Temporomandibular Joint Disc Displacement; Temporomandibular Joint Osteoarthritis

Summary: temporomandibular joint (tmj) diseases or dysfunctions affects many patients. surgical treatment is planned when non-invasive interventions have failed. still, much is not known regarding aetiology of tmj diseases and how and why the disease develops over time. the study aims to investigate synovial tissue, synovial fluid and clinical characteristics for patients with tmj diseases or dysfunctions designated for surgery. patient samples and clinical variables will be analysed in relation to tmj diagnosis and related to surgical outcome. the study is a cohort observational study.

tmj disc displacement is common, affecting 20-30% of the population. some of these patients will eventually need health-care attention. patients with tmj osteoarthritis (oa) or chronic inflammatory arthritis (cia) are not that common, prevalence numbers are lacking. these tmj diseases or dysfunctions can severely affect the patients' well-being because of local pain, chewing problems, psychosocial impact, amongst others. treatment is primarily non-invasive to its character where orthotic splint, physiotherapy, medication, or other treatments can be evaluated. patients who do not respond to these efforts might have surgery. arthroscopy is a minimal invasive intervention with a described success rate from 50-90%. from the patients', the society and the surgeons' point of view, better individual pre-operative prognostication is valuable. tmj disc displacement, oa and cia is not fully characterised in terms of aetiopathogenesis. there are studies investigating components of extra cellular matrix and cytokines tmj. the multitude of proteins still not studied may contribute in an unknown fashion to new insights in aetiology and to new treatment opportunities. the aim of the study is to characterise synovial tissue, synovial fluid, and clinical parameters and relate them to the specific tmj diagnosis but also to each others. a secondary aim is to relate the outcome of surgery to both clinical and tissue variables in order to determine if there are factors that might function as predictors of outcome. a tertiary aim is to investigate if patients who suddenly develops disc displacement without reduction (ddwor) without any prior signs or symptoms from the tmj differs in their tissue or clinical characteristics compared to patients who develops ddwor after having prior signs or symptoms from the tmj.

Eligibility criteria:
inclusion criteria: * age 18 or older * diagnosis ddwor, ddwr, oa, or cia * conservative treatment (i.e. orthotic split, physiotherapy, medication) tried for at least 3-6 months without success exclusion criteria: * earlier tmj surgery * age under 18 years * patients not able to give informed consent
icf in cochlear implant users

Conditions: Hearing Loss

Summary: the current project proposes a multi-center prospective follow-up cohort study aiming to realize an international framework to classify human functioning and disability in cochlear implant (ci) recipients using a standardized icf framework. for this, icf qualifiers which denote the magnitude of the level of health or severity of the problem will be quantified to enable comparison of data across countries and health-care disciplines. adult subjects (≥18 years old) eligible for cochlear implantation, considering the local criteria of reimbursement, will be assessed one month preoperatively and six months post the activation of the speech processor using three audiological examinations, evaluating the participants' localization abilities, speech recognition and hearing thresholds, and six questionnaires, each evaluating different aspects of daily life functioning and disability in hearing-impaired persons.


Eligibility criteria:
inclusion criteria: 1. general * adults aged 18 years or older with postlingual hl * signed and dated informed consent, informed permission and/or minors assent. * willingness to participate in evaluations, test sessions, and medical follow-up sessions as defined in the protocol. * physical and mental competence to participate in fitting of the device and follow-up sessions as defined in the protocol. * fluency in the language of the implanting centre. 2. audiological * completion of hearing assessment battery showing suitability of the ci candidates. * compliance with cochlear implant candidate selection criteria of the implanting centre. * first cochlear implantation 3. medical * patent cochlea, as evidenced by high-resolution computed tomography (hrct) and/or magnetic resonance imaging (mri). exclusion criteria: 1. general * re-implantation of the cochlear implant * no motivation to participate in the study and/or unreasonable expectations. 2. medical * presence of contra-indications for surgery in general and cochlear implantation in particular. * presence of central auditory lesions. * autoimmune disease, meningitis or ossification of the cochlea. * radiological evaluation indicating malformation or obstruction of the cochlea. * unstable psychological status. * any disorder that may relate to an increased risk of skin flap problems * having received chemotherapy * be a burn victim 3. use of one of the following electrodes for implantation * compressed * split * any type of custom made electrodes

Keywords: cochlear implantation international classification of functioning, disability and health
egfr-targeted therapy for gastric cancer

Conditions: Adenocarcinoma of the Stomach

Summary: based on targeted ngs panel results, metastatic gastric cancer patients with gene amplifications will receive either anti-egfr antibody (gc-1118) in combination with weekly paclitaxel as a second-line therapy.

participants will receive each treatment if the gastric cancer tissue sample reveals either egfr gene amplification or strong (3+ or 2+) egfr immunostaining

Eligibility criteria:
key inclusion criteria 1. histologically-proven gastric and gastroesophageal junction adenocarcinoma 2. refractory to first-line chemotherapy for metastatic disease 3. presence of at least 1 measurable lesion according to recist version 1.1 4. egfr gene amplification or strong (3+ or 2+) egfr immunostaining key exclusion criteria 1.prior exposure to taxane or egfr-targeted therapy

Keywords: egfr
physiotherapy in hypoxic aecopd patients

Conditions: COPD Exacerbation

Summary: hypoxia is considered a key player in many of the comorbidities that characterize copd, such as pulmonary hypertension, skeletal muscle dysfunction, and systemic inflammation. these comorbidities are worsened during an exacerbation due to prolonged bed rest and treatment with steroids, showing a reduction in the quality of life, exercise tolerance, and a greater risk of death in these patients. therefore, a better understanding of the safety and effectiveness of exercise training for aecopd patients with resting hypoxemia is needed.


Eligibility criteria:
inclusion criteria: * patients of both sexes * a diagnosis of copd made according to the criteria of the american thoracic society (ats) * with hypoxemia at rest defined as mean arterial oxygen saturation below 90% * agreed to participate exclusion criteria: * unstable cardiovascular disease * orthopedic diseases in the upper and lower limbs * being in icu or use of mechanical ventilation * motor sequelae from a neurological or cognitive impairment that interfere with the evaluation and the treatment * contraindications of electrotherapy
study to detect changes in urinary and gut microbiome during androgen deprivation therapy and radiation therapy in patients with prostate cancer

Conditions: Stage I Prostate Cancer AJCC v7; Stage II Prostate Cancer AJCC v7; Stage IIA Prostate Cancer AJCC v7; Stage IIB Prostate Cancer AJCC v7; Stage III Prostate Cancer AJCC v7; Stage IV Prostate Cancer AJCC v7

Summary: this study collects urine and stool samples to determine the ability to identify changes in the microbiome (bacteria, fungi, and viruses that live in the gut and urine) of patients with prostate cancer during androgen deprivation therapy and radiation therapy. radiation therapy has the potential to harm the genitourinary area or the bowel, causing a feeling of urgency or increased inflammation in the area. the radiation therapy is designed to not irradiate the bowel and bladder areas, but there is still some radiation exposure. the gut microbiome has been associated with differences in inflammation as well as producing molecules that influence healing. the purpose of this study is to see whether the microbiome may contribute to the healing of the organs exposed to radiation. information learned from this study may help researchers discover a new risk factor that could be manipulated to improve the quality of life in patients with prostate cancer.

primary objective: i. to determine the feasibility of identifying changes in urine and gut microbiomes during androgen deprivation therapy and radiation therapy for prostate cancer. secondary objective: i. to explore associations between baseline microbiomes and urinary or gastrointestinal radiation toxicity by common terminology criteria for adverse events (ctcae) and patient reported outcomes (pro). outline: patients undergo collection of stool and urine samples within 2 weeks before hormone therapy or radiation therapy, after hormone therapy but before start of radiation therapy, and after completion of radiation therapy. patients also complete a series of questionnaires prior to starting radiation therapy, mid-way through radiation therapy, and after completion of radiation therapy (within 1-3 weeks, at 3 months, and then every 6 months until 3 years from radiation completion). patients' medical records are also reviewed.

Eligibility criteria:
inclusion criteria: * pathologically confirmed prostate cancer, with a plan to receive radiation therapy for either definitive (cohort a) or salvage (cohort b) therapy. patients without planned androgen deprivation therapy (adt) will be accrued to cohort c * cohort a will be restricted to gleason grade group 3 or higher (4+3 or 8-10) so that androgen deprivation will be indicated * cohort b will not be restricted by gleason grade but will require rising prostate-specific antigen (psa) and a plan for adt with salvage radiation * cohort c will be prostate cancer patients in whom definitive or salvage radiation is planned without adt * patients must be age 18 or older * willing to provide urine and stool samples at specified time points exclusion criteria: * men with inflammatory bowel disease or pre-existing cystitis will be excluded
sodium chloride vs. glucose solute as a volume replacement therapy during decongestion in acute heart failure

Conditions: Acute Heart Failure; Congestion; Heart Failure

Summary: the aim of the study is to compare the differences in diuretic, natriuretic and clinical response to decongestion in patients receiving different replacement fluid regimens (0.9% sodium chloride vs 5% glucose) in acute heart failure.


Eligibility criteria:
inclusion criteria: * patients \>18 years old who sign the informed consent * the primary cause of hospitalization is acute heart failure with a need for intravenous furosemide * the start of the study within 24h of hospital admission exclusion criteria: * need for inotropic support * end stage renal disease on dialysis * serum sodium \> 148mmol/l or \< 130 mmol/l.

Keywords: acute heart failure decongestion volume replacement sodium chloride congestion
xenon inhalation for treatment of panic disorder

Conditions: Panic Disorder

Summary: this study is a double-blind, randomized, placebo-controlled, clinical trial in parallel groups in patients with panic disorder.


Eligibility criteria:
inclusion criteria: * primary diagnosis of panic disorder according to dsm-5. * male and female patients ≥18 years of age. exclusion criteria: * history of schizophrenia, bipolar and other psychotic disorders. * patients with underlying pulmonary disease, chronic obstructive pulmonary disease (copd), asthma, severe lung disease and/or baseline oxygen saturations \<92% or any other respiratory conditions / diseases that may affect the respiratory function. * currently undergoing targeted empirically-driven psychotherapy for panic disorder or panic disorder-related symptoms. * currently undergoing exposure-based psychotherapy for any condition.
prophylaxis of gvh in elderly patients receiving haploidentical allogenic hematopoietic stem cell trasnplantation use of a low dose anti-lymphocytic serum

Conditions: Hematological Malignancy

Summary: the aim of this trial is to evaluate the efficacy of gvh prophylaxis reinforced by low-dose thymoglobulin administered at the end of aplasia after haploidentical allogeneic transplantation. patients will receive a single infusion of thymoglobulin at a dose of 1 mg/kg between 48h and 72h after emergence from aplasia, and will be followed for 12 months.


Eligibility criteria:
inclusion criteria: * adults aged ≥ 60 or aged 50 to 59 with comorbidities (hct-ci10 score ≥ 3), * hematological malignancies except myeloproliferative syndrome and myelodysplastic syndrome, * patient having received an allograft within ≤ 35 days, performed with the following modalities: * first allogeneic transplant, * haploidentical donor, * peripheral stem cell transplant, * non-myeloablative "baltimore"-type conditioning, delivered as standard in routine care, as reported in the literature (fludarabine, cyclophosphamide, total body irradiation), * standard gvhd prophylaxis in the context of haploidentical transplants (post-transplant cyclophosphamide, ciclosporin a and mycophenolate mofetil). * patient discharged from aplasia within ≤ 35 days, * signed informed consent form, * affiliation with a social security. exclusion criteria: * previous allogeneic or organ transplant, * presence of signs of gvhd, * contraindications to treatment with thymoglobuline®, * hypersensitivity to rabbit proteins or to any of the excipients listed in the "composition" section of the summary of product characteristics, * pregnant women or may become pregnant (without effective contraception) or breast-feeding, * persons in emergency situations or unable to give informed consent form, * adult with a legal protection measure (adult under guardianship, curatorship or safeguard of justice), * unable to comply with medical follow-up for geographical, social or psychological reasons.
effects of global postural re-education versus laser-guided exercise in non-specific chronic low back pain

Conditions: Pain, Back

Summary: effects of global postural re-education versus laser-guided supervised exercise in individuals with non-specific chronic low back pain

the objective of this study will be to investigate the effectiveness of gpr or lge, in addition to pne and home exercise program. the primary outcomes will be pain intensity, disability, and fingertip to floor test. the secondary outcomes will be pain catastrophizing, kinesiophobia and depression.

Eligibility criteria:
inclusion criteria: * aged between 18 and 45 years. * diagnosed with nslbp. * experiencing nsclbp for ≥ 3 months and score at least 3/10 on the numerical pain rating scale (nprs). exclusion criteria: * diagnosed with a condition that hinders their ability to engage in physical exercise (e.g., uncontrolled diabetes, cardiovascular disease, orthopedic impairments; balancing problems). * diagnosed with severe spine conditions (such as fractures, tumors, ankylosing spondylitis, or inflammatory disorders). * diagnosed with neurological problems (such as spine nerve problems or cauda equina syndrome) * diagnosed with mental illness or severe cognitive impairment that made it impossible to follow the pne program. * with a physical condition that made it impossible to complete the pne program (the timed "up and go" test had to be completed in 10 seconds at a minimum). * receiving alternate therapy for related pathologies (myopathies and neurological diseases) that prevented them from completing the pne program.
trial of concurrent versus sequential tamoxifen with radiotherapy in breast cancer patients

Conditions: Pulmonary Fibrosis; Breast Cancer

Summary: two hundred and sixty patients with breast cancer will be accrued into the study. after inclusion in the study, all the patients will be randomized into two arms. arm 1 will receive tamoxifen given concurrently with radiotherapy while in arm 2 radiotherapy will be given followed by tamoxifen sequentially. the patients will be stratified for the following factors: a) bcs (breast conservative surgery) versus mrm (modified radical mastectomy) and b) central lung distance (cld) \> 2 cm. patients in both arms will continue tamoxifen for a period of 5 years. the patients will be evaluated by high-resolution computed tomography (hrct) (baseline and at 2 years), serum transforming growth factor (tgf) beta levels (baseline and at 6 months) and diethylenetriaminepentaacetic acid (dtpa) aerosol clearance half life (baseline and at 6 months).


Eligibility criteria:
inclusion criteria: * patients with large operable lesions (pt/ct \> 5 cm) or locally advanced breast cancers undergoing modified radical mastectomy or breast conservative surgery-(bcs) who need adjuvant post operative radiotherapy * patients post mastectomy requiring radiotherapy because of nodal positivity * completed planned chemotherapy schedule * er and/or pr positive patients * patients decided to be put on tamoxifen * patients reliable for follow up exclusion criteria: * patients with bct who have pt1 or pt2 breast lesions (n0,n1) * patients for palliative radiotherapy to the chest wall/breast/supraclavicular fossa * any patient requiring radiation to the axillary or internal mammary area * recurrent disease or metastatic disease * patients on concurrent chemotherapy and radiation

Keywords: breast cancer pulmonary fibrosis tamoxifen radiotherapy
a study of treatment preference during cheek contouring comparing restylane® subq with and without the addition of lidocaine hydrochloride

Conditions: Facial Tissue Augmentation

Summary: the objectives of this study are to evaluate the pain-relieving effect and safety of adding lidocaine hydrochloride to restylane subq and to evaluate the esthetic improvement obtained. the study products will be administered in the cheek.

the restylane subq gel is intended to be used for facial tissue augmentation. the lidocaine content is designed to reduce the subject's pain during treatment. the objectives of this split-face designed study are to evaluate the pain-relieving effect and safety of adding lidocaine hydrochloride to restylane subq and to evaluate the esthetic improvement obtained with the dermal filler using the global esthetic improvement scale (geis).

Eligibility criteria:
inclusion criteria: * 18 years of age or older. * intent to undergo contouring of both cheeks with 1.5 to 2 ml restylane subq per cheek. * sufficient symmetry of the face in order to ensure similar volume to be injected, similar injection technique and time for injection. * signed informed consent. exclusion criteria: * surgery in the midface including aesthetic facial surgical therapy, sinus surgery or dental root surgery within the past 12 months. * chronic infection in head and neck region. * ongoing infections in mouth. * tendency for edema, puffiness or swelling over the zygomatic prominence. * active skin disease, inflammation or related conditions, such as infection, psoriasis and herpes zoster near or on the area to be treated. * previous hypersensitivity to hyaluronic acid or local anesthetics. * concomitant anticoagulant therapy and therapy with inhibitors of platelet aggregation within 10 days prior to treatment, or a history of bleeding disorders. * cancerous or pre-cancerous lesions in the area to be treated. * previous tissue augmenting therapy in the area to be treated with non-permanent filler, laser treatment, or chemical peeling during the last 6 months. * permanent implant placed in the area to be treated. * reduced sensibility in the facial region e.g. due to trauma, facial pareses, previous tissue augmenting therapy, aesthetic facial surgical therapy, laser treatment, or peeling. * pregnancy or breast feeding. * participation in any other clinical study within 30 days prior to inclusion. * other condition preventing the subject to entering the study in the investigator's opinion e.g. subjects not likely to avoid other facial cosmetic treatments below the level of the upper orbital rim, subjects anticipated to be unreliable or incapable of understanding the vas assessment, insufficient tissue support or cover of the treatment area.
impact of different perioperative tourniquets on blood loss and surgeon satisfaction in total knee arthroplasty

Conditions: Total Knee Arthroplasty

Summary: the present study investigates the impact of two different perioperative tourniquets with different closing features on operative blood los, surgical field quality and surgeon satisfaction.


Eligibility criteria:
inclusion criteria: * inidication for a total knee arthroplasty * approval for surgery by the department of anesthesia exclusion criteria: * open wounds of the lower extremities * acute or chronic infections of the lower extremities